Yoon Hyung-Joon, Kim Eun Taeg, Song Changho
Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Republic of Korea.
Biomedical Research Institute, Pusan National University School of Medicine, Busan, Republic of Korea.
Transl Cancer Res. 2025 Jul 30;14(7):4034-4045. doi: 10.21037/tcr-2025-307. Epub 2025 Jul 25.
Cervical cancer (CC) is the fourth most common cancer in women. Prognostic biomarkers for CC, particularly squamous cell carcinoma (SCC), are limited despite their clinical significance. ANKRD22, an ankyrin repeat domain protein, has been implicated in several cancers, but its role in CC remains unclear. In this study, we aimed to analyze the relationship between expression and the prognosis of patients with CC, especially SCC.
Gene expression profiles were obtained from GEO datasets (GSE63514, GSE6791), and RNA sequencing and clinical data were obtained from The Cancer Genome Atlas. Clinical characteristics included age, Federation of Gynecology and Obstetrics 2009 stage, histological grade, lympho-vascular space invasion, and treatment response. Patients were stratified by expression, and survival analyses were conducted using Kaplan-Meier and Cox regression models.
expression was significantly lower in CC tissues than in normal tissues. In SCC patients, the lower expression was associated with worse overall survival (OS) [P=0.008, hazard ratio (HR) =0.494, 95% confidence interval (CI): 0.290-0.840] and progression-free survival (PFS) (P=0.01, HR =0.510, 95% CI: 0.295-0.880). Multivariate Cox regression analysis identified downregulation as an independent prognostic factor. Lower expression was also correlated with higher histological grade.
downregulation is associated with poor prognosis in SCC of the cervix. While these findings suggest prognostic relevance, further experimental studies are necessary to validate 's clinical utility.
宫颈癌（CC）是女性中第四大常见癌症。尽管其具有临床意义，但CC，尤其是鳞状细胞癌（SCC）的预后生物标志物仍然有限。锚蛋白重复结构域蛋白ANKRD22已涉及多种癌症，但其在CC中的作用仍不清楚。在本研究中，我们旨在分析ANKRD22表达与CC患者，尤其是SCC患者预后之间的关系。
从GEO数据集（GSE63514、GSE6791）获得基因表达谱，并从癌症基因组图谱获得RNA测序和临床数据。临床特征包括年龄、2009年国际妇产科联盟分期、组织学分级、淋巴血管间隙浸润和治疗反应。根据ANKRD22表达对患者进行分层，并使用Kaplan-Meier和Cox回归模型进行生存分析。
CC组织中ANKRD22表达明显低于正常组织。在SCC患者中，ANKRD22低表达与较差的总生存期（OS）[P = 0.008，风险比（HR）= 0.494，95%置信区间（CI）：0.290 - 0.840]和无进展生存期（PFS）（P = 0.01，HR = 0.510，95%CI：0.295 - 0.880）相关。多变量Cox回归分析确定ANKRD22下调为独立预后因素。较低的ANKRD22表达也与较高的组织学分级相关。
ANKRD22下调与宫颈SCC的不良预后相关。虽然这些发现表明其与预后相关，但需要进一步的实验研究来验证ANKRD22的临床效用。
